Slide 1: Immuron CEO to present at The Watchlist
Immuron CEO, Steven Lydeamore to present at The Watchlist Melbourne, Australia, April 23 , 2024 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting a
Slide 2: Travelers' diarrhea and Immuron platform technology
Travelers’ diarrhea (TD) TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any
Slide 3: Forward-Looking Statements
FORWARD - LOOKING STATEMENTS : This press release may contain “forward - looking statements” within the meaning of Section 27 A of the Securities Act of 1933 and Section 21 E of the Securities Exchange Act of 1934 , each as amended . Such statements include, but are not limited to, any statements re
Slide 4: The Watchlist April 2024
1 1 THE WATCHLIST INVESTOR PRESENTATION 23 APRIL 2024 S t e v e n L y d e am o r e - C E O NASDAQ: IMRN ASX: IMC
Slide 5: Certain statements made in this presentatio n are forward - looking statements and are
2 Certain statements made in this presentatio n are forward - looking statements and are based on Immuron’s current expectatio ns, estimates and projections. Words such as “anticipates ,” “expects,” “intends ,” “plans,” “believes ,” “seeks,” “estimates ,” “guidanc e” and similar expressio ns are int
Slide 6: Executive Summary
3 EXECUTIVE SUMMARY C o m p a n y O v e r v i e w B us i ness Update Results & Outlook • Two commercially available oral immunotherapeutic products – Travelan® and Protectyn® • 4 clinical programs: Travelan®(IMC: Phase 2 CHIM trial), Travelan®(USU: Phase 4 field study), CampETEC (NMRC: Phase 2 CHIM
Slide 7: IMM-124E Billion Dollar Market - High Unmet Need
4 IMM - 12 4 E BILLION DOLLAR MARKET - HIGH UNMET NEED Indu s t r y t a ilwi nd s Travel picking up significantly following COVID lockdowns Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% 1 Frequent Symptoms 30% - 70% of travelers experience travell
Slide 8: Technology Platform
TECHNOLOGY PLATFORM Bovine colostrum is the first milk of cows after calving. It is rich in immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, growth factors and bioactive peptides. Colostrum has higher levels of protein, fat, vitamins, and minerals when compared to milk. This enables full dev
Slide 9: Travelan Sales Continue Strong Growth
6 TRAVELAN® SALES CONTINUE STRONG GROWTH FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Global FYTD Mar 2024 AUD$2.8 million up 234% on pcp Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% o
Slide 10: Status of Product Portfolio and Key Milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES US Department of Defense grant of US$4.45 million to examine a dosing regimen for Travelan® more suited for use by the military • Market evaluation by Lumanity confirms the Traveler’s Diarrhea market opportunity for IMM - 124E (Travelan®) • IMM - 124E (
Slide 11: Near Term Milestones Anticipated to Drive Value
8 NEAR TERM MILESTONES ANTICIPATED TO DRIVE VALUE • Clinical Study Report • End of Phase 2 FDA meeting • Topline results for IMM - 124E ETEC2 clinical trial • 100% of patients enrolled • Completion of In - patient phase ETEC 2 CHIM 3 clinical trial • IRB Approval 4 • Initiated IMM - 124E ETEC 2 CHIM
Slide 12: Immuron's Clinical Programs - Opportunity Assessment
9 IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM - 124E (hyperimmune bovine colostrum) as a prescription medication has the potential to address this unmet need › Primary care physicians (PCP)s impressed with clinical efficacy endpoint targets demonstrating > 80%
Slide 13: IMM-124E Phase Strategy
10 IMM - 124E PHASE 3 STRATEGY • Trial duration ~ 2 years • End of Phase 3 FDA meeting • BLA 3 submission • Initiate Phase 3 • Phase 3 FDA meeting • Clinical Study Report • End of Phase 2 FDA meeting • Phase 1 clinical study (Baltimore, 1996) • Phase 2 clinical study (Poland, 2000) • FDA 1 IND 2 app
Slide 14: World First Triple Mechanism of Action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI 11 I MM - 529 Indication / Target Population IMM - 529 will be indicated for the treatment of recurrent C. difficile infection Product Description / Mechanism of Action • Novel antibody - containing therapeutic which neutralizes C. difficile but does no
Slide 15: Contact Information
12 EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172 STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION:
Slide 16: Scientific References
1 3 1 3 SCIENTIFIC REFERENCES T r a v e l a n® (I MM - 124 E ) Scandinavian Journal of Gastroenterology, 46:7 - 8, 862 - 868, DOI: 10.3109/00365521.2011.574726 Travelan® has been shown to reduce both the incidence and severity of ETEC - induced diarrhea in up to 90% of volunteers Military Health Sys